Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions

C. De Cicco, G. Trifirò, M. Intra, G. Marotta, A. Ciprian, A. Frasson, G. Prisco, A. Luini, G. Viale, G. Paganelli

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to evaluate the feasibility of sentinel node (SN) biopsy in occult breast lesions with different radiopharmaceuticals and to establish the optimal lymphoscintigraphic method to detect both occult lesions and SNs (SNOLL: sentinel node and occult lesion localisation). Two hundred and twenty-seven consecutive patients suspected to have clinically occult breast carcinoma were enrolled in the study. In addition to the radioguided occult lesion localisation (ROLL) procedure, using macroaggregates of technetium-99m labelled human serum albumin (MAA) injected directly into the lesion, lymphoscintigraphy was performed with nanocolloids (NC) injected in a peritumoral (group I) or a subdermal site (group II). In group III, a sole injection of NC was done into the lesion in order to perform both ROLL and SNOLL. Overall, axillary SNs were identified in 205 of the 227 patients (90.3%). In 12/62 (19.4%) patients of group I and 9/79 (11.4%) patients of group III, radioactive nodes were not visualised, whereas SNs were successfully localised in 85 of 86 patients of group II (P

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume31
Issue number3
DOIs
Publication statusPublished - Mar 2004

Keywords

  • Breast neoplasms
  • Lymphoscintigraphy
  • Non-palpable lesion
  • Radionuclide imaging
  • Sentinel node

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint

Dive into the research topics of 'Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions'. Together they form a unique fingerprint.

Cite this